To monitor the safety of Metalyse® in clinical practice in patients with acute myocardial infarction over a period of 6 years as required by Korean authorities, with the following observations: 1. Unexpected adverse drug reactions 2. Frequency and nature of adverse events (AEs) 3. Factors on the safety and efficacy profile of the Metalyse® Injection. Efficacy of Metalyse® was also assessed.
Study Type
OBSERVATIONAL
Enrollment
987
30-day mortality after the Metalyse® Injection
Time frame: 30 days
Outcome assessment - 'Improvement' or 'Failure'
'Improvement' was defined as survival on 30 days and 'Failure' as death on 30 days after the Metalyse treatment.
Time frame: 30 days
Number of patients with adverse events
Time frame: up to 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.